CM
BMRN icon

Caption Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Caption Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-52,000
Closed -$2.82M – 1594
2025
Q3 		$2.82M Buy
52,000
+26,500
+104% +$1.52M 0.02% 708
2025
Q2 		$1.4M Sell
25,500
-18,000
-41% -$1.06M 0.02% 833
2025
Q1 		$3.08M Sell
43,500
-1,500
-3% -$101K 0.03% 539
2024
Q4 		$2.96M Buy
+45,000
New +$3.01M 0.03% 557
2024
Q3 		– Sell
-47,700
Closed -$3.93M – 1288
2024
Q2 		$3.93M Buy
47,700
+32,700
+218% +$2.72M 0.06% 322
2024
Q1 		$1.31M Buy
+15,000
New +$1.34M 0.02% 668
2023
Q4 		– Sell
-25,300
Closed -$2.24M – 1356
2023
Q3 		$2.24M Sell
25,300
-219,200
-90% -$19.5M 0.03% 549
2023
Q2 		$21.2M Buy
244,500
+108,300
+80% +$10.2M 0.38% 55
2023
Q1 		$13.2M Buy
136,200
+94,200
+224% +$9.77M 0.26% 87
2022
Q4 		$4.35M Sell
42,000
-18,000
-30% -$1.69M 0.07% 334
2022
Q3 		$5.09M Buy
+60,000
New +$5.34M 0.07% 345
2022
Q2 		– Sell
-72,500
Closed -$5.59M – 1468
2022
Q1 		$5.59M Buy
72,500
+30,000
+71% +$2.51M 0.07% 380
2021
Q4 		$3.75M Buy
+42,500
New +$3.51M 0.04% 550
2021
Q2 		– Sell
-140,400
Closed -$10.6M – 1307
2021
Q1 		$10.6M Sell
140,400
-226,400
-62% -$18.5M 0.23% 105
2020
Q4 		$32.2M Buy
366,800
+148,700
+68% +$11.8M 0.73% 17
2020
Q3 		$16.6M Buy
218,100
+152,100
+230% +$15.4M 0.39% 47
2020
Q2 		$8.14M Sell
66,000
-138,000
-68% -$13.7M 0.27% 90
2020
Q1 		$17.2M Buy
204,000
+59,900
+42% +$5.16M 0.97% 7
2019
Q4 		$12.2M Buy
+144,100
New +$10.9M 0.41% 46
2019
Q3 		– Sell
-38,000
Closed -$3.25M – 714
2019
Q2 		$3.25M Buy
38,000
+24,500
+181% +$2.1M 0.16% 175
2019
Q1 		$1.2M Sell
13,500
-20,600
-60% -$1.91M 0.07% 314
2018
Q4 		$2.9M Buy
+34,100
New +$3.24M 0.23% 130
2018
Q3 		– Sell
-10,000
Closed -$942K – 515
2018
Q2 		$942K Hold
10,000
– – 0.07% 257
2018
Q1 		$811K Buy
+10,000
New +$858K 0.12% 165

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caption Management's BMRN Position: Q1 2026 in Review

Caption Management increased its BioMarin Pharmaceuticals (BMRN) stake by 184% in Q1 2026, buying an estimated $2.09M and bringing the position to 55,300 shares worth $3.12M. The position accounts for 0.02% of the portfolio, ranked #682.

Caption Management first reported a position in BMRN in Q4 2017 and has held it in 17 quarters since. The position peaked at $9.87M in Q2 2023. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Caption Management held 55,300 shares of BioMarin Pharmaceuticals worth $3.12M as of Q1 2026.
  • Caption Management bought 35,800 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $2.09M.
  • BioMarin Pharmaceuticals made up 0.02% of Caption Management's portfolio in Q1 2026, its #682 holding.
  • Caption Management first reported a position in BioMarin Pharmaceuticals in Q4 2017 and has held it in 17 quarters since.
  • Caption Management's BioMarin Pharmaceuticals position peaked at $9.87M in Q2 2023.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.